Press release
Number of voting rights and shares as of July 31
06 Sep 2017 17:45 CEST
Company Name
FR0004032746-ALXP
ISIN
FR0004032746
Total number of voting rights and shares
Information concerning the total number of voting rights and shares, provided pursuant to article L. 233-8 II of the Code de commerce (the French Commercial Code) and article 222-16 of the Règlement Général de l’Autorité des Marchés Financiers (Regulation of the French stock market authority).
|
Date |
Total number of shares |
Number of existing voting rights (GROSS) |
Number of existing voting rights (NET) |
|
07/31/2017 |
61, 607, 363 |
63, 062, 437 |
53, 831, 668 |
About Neovacs
Listed on Euronext Growth since 2010, Neovacs is today a leading biotechnology company focused on an active immunotherapy technology platform (Kinoids) with applications in autoimmune and/or inflammatory diseases. On the basis of the company’s proprietary technology for inducing a polyclonal immune response (covered by five patent families that potentially run until 2032) Neovacs is focusing its clinical development efforts on IFNα-Kinoid, an immunotherapy being developed for the indication of lupus and dermatomyositis. Neovacs is also conducting preclinical development works on other therapeutic vaccines in the fields of auto-immune diseases, oncology, allergies and Type 1 diabetes. The goal of the Kinoid approach is to enable patients to have access to safe treatments with efficacy that is sustained in these life-long diseases. www.neovacs.fr
For more information on Neovacs, visit www.neovacs.fr
NEOVACS – Investor Relations
Charlène Masson
+33 (0)1 53 10 93 00
Investor Relations / Financial Communications – Life Science Advisors
Chris Maggos
Connect_neovacs_regulated-information-reglementee30062017.pdf